ASCO Lung Cancer Roundtable - NSCLC - The CITYSCAPE Trial: Anti TIGIT & Immune Checkpoint Inhibitor

dbrock's picture
Trial Updates - Anti-TIGIT and NSCLC PDL1 The CITYSCAPE Trial - Adding Tiragolumab (Anti-TIGIT) to an Immune Checkpoint Inhibitor - A Better Treatment Option?
H. Jack West, MD, Founder, President and CEO
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.

Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon.

Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is Trial Updates - Anti-TIGIT and NSCLC PDL1, and the CITYSCAPE Trial - Adding Tiragolumab (Anti-TIGIT) to an Immune Checkpoint Inhibitor - A Better Treatment Option?

 

 

To join the conversation, visit https://cancergrace.org/forum.

 

 

Video Language: 

 

Join the Conversation

Please feel free to offer comments and raise questions in our
discussion forums.

 Join The conversation